Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Investigating Sex Differences in Fetal Antiretroviral Drug Disposition

FY 2018-19

Summary
Combination antiretroviral (ARV) therapy during pregnancy is increasingly effective in reducing risk of vertical human immunodeficiency virus (HIV) transmission, however the fetal toxicity of widely administered ARV drugs remains poorly described and existing literature often fails to account for sex as a variable. Evidence of sex-linked toxicities in ARV exposed children suggests differing drug disposition between male and female subjects that may be explained by variable expression of drug transporters. These transporters are expressed at tissue barriers throughout the body and highly regulate the ARV drug exposure of vital tissues, such as the brain. Furthermore, sex and age have been identified as important factors influencing drug transporter expression in human and animal models. Using an ARV drug exposed mouse model, my research aims to compare male and female fetal expression of multi-drug transporters and penetration of ARV drugs into fetal tissues, in order to better understand sex-linked toxicities of antiretroviral therapy, and highlight the need for more effective design of HIV treatment regimens during pregnancy.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
417489
Name
Gilmore Julian
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating Sex Differences in Fetal Antiretroviral Drug Disposition
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adverse Drug Reactions; Antiretroviral Drugs; Combination Antiretroviral Therapy; Drug Disposition; Drug Transport; Human Immunodeficiency Virus; Mass Spectrometry; Protein Expression; Quantitative Polymerase Chain Reaction; Sex Differences
Abstract
Combination antiretroviral (ARV) therapy during pregnancy is increasingly effective in reducing risk of vertical human immunodeficiency virus (HIV) transmission, however the fetal toxicity of widely administered ARV drugs remains poorly described and existing literature often fails to account for sex as a variable. Evidence of sex-linked toxicities in ARV exposed children suggests differing drug disposition between male and female subjects that may be explained by variable expression of drug transporters. These transporters are expressed at tissue barriers throughout the body and highly regulate the ARV drug exposure of vital tissues, such as the brain. Furthermore, sex and age have been identified as important factors influencing drug transporter expression in human and animal models. Using an ARV drug exposed mouse model, my research aims to compare male and female fetal expression of multi-drug transporters and penetration of ARV drugs into fetal tissues, in order to better understand sex-linked toxicities of antiretroviral therapy, and highlight the need for more effective design of HIV treatment regimens during pregnancy.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Gilmore, Julian
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~